Compare RSVR & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RSVR | COLL |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 681.9M | 768.2M |
| IPO Year | 2020 | 2015 |
| Metric | RSVR | COLL |
|---|---|---|
| Price | $10.10 | $24.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $13.00 | ★ $44.00 |
| AVG Volume (30 Days) | 53.1K | ★ 533.8K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.33 | N/A |
| EPS | 0.07 | ★ 0.64 |
| Revenue | $175,664,491.00 | ★ $780,567,000.00 |
| Revenue This Year | $8.25 | $6.59 |
| Revenue Next Year | $5.49 | $1.89 |
| P/E Ratio | $145.43 | ★ $39.44 |
| Revenue Growth | ★ 10.69 | N/A |
| 52 Week Low | $7.15 | $21.43 |
| 52 Week High | $13.39 | $50.79 |
| Indicator | RSVR | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 53.68 |
| Support Level | $9.98 | $21.67 |
| Resistance Level | $10.22 | $26.39 |
| Average True Range (ATR) | 0.38 | 0.92 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 33.82 | 44.20 |
Reservoir Media Inc is an independent music company. The company operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the U.S. Music Publishing segment engaged in the acquisition of interests in music catalogs to earn royalties and signing songwriters to agreements of future delivery of songs. The Recorded Music segment involve the acquisition of sound recording catalogs and the discovery and development of recording artists and the marketing, distribution, sale and licensing of the music catalog.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.